​

Chemomab Therapeutics (CMMB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

CMMB Stock Rating

Chemomab Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

CMMB Price Target Upside V Benchmarks

TypeNameUpside
StockChemomab Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.22$1.22$1.22
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2521---3
May, 2521---3
Apr, 2521---3
Mar, 2521---3
Feb, 2521---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 16, 2025OppenheimerOutperformOutperformhold
Jul 25, 2024OppenheimerOutperformOutperformhold
May 06, 2024OppenheimerOutperformupgrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.06-----
Avg Forecast$-0.12$-0.30$-0.27$-0.27$-0.28$-0.31
High Forecast$-0.12$-0.30$-0.23$-0.16$-0.17$-0.31
Low Forecast$-0.12$-0.30$-0.31$-0.38$-0.39$-0.31
Surprise %1616.67%-----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$24.40M$36.20M-
High Forecast---$24.40M$36.20M-
Low Forecast---$24.40M$36.20M-
Surprise %------

Net Income Forecast

$-95M $-80M $-65M $-50M $-35M $-20M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-24.16M-----
Avg Forecast$-27.02M$-71.28M$-63.45M$-63.45M$-65.80M$-72.85M
High Forecast$-27.02M$-71.28M$-54.39M$-38.07M$-39.48M$-72.85M
Low Forecast$-27.02M$-71.28M$-72.51M$-88.83M$-92.12M$-72.85M
Surprise %-10.61%-----

CMMB Forecast FAQ

Is Chemomab Therapeutics stock a buy?

Chemomab Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Chemomab Therapeutics is a favorable investment for most analysts.

What is Chemomab Therapeutics's price target?

Chemomab Therapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.22.

How does Chemomab Therapeutics stock forecast compare to its benchmarks?

Chemomab Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Chemomab Therapeutics over the past three months?

  • June 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Chemomab Therapeutics’s EPS forecast?

Chemomab Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.3, marking a -85.44% decrease from the reported $-2.06 in 2023. Estimates for the following years are $-0.27 in 2025, $-0.27 in 2026, $-0.28 in 2027, and $-0.31 in 2028.

What is Chemomab Therapeutics’s revenue forecast?

Chemomab Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $24.4M for 2026, $36.2M for 2027, and $0 for 2028.

What is Chemomab Therapeutics’s net income forecast?

Chemomab Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-71.282M, representing an 195.06% increase from the reported $-24.159M in 2023. Projections indicate $-63.45M in 2025, $-63.45M in 2026, $-65.8M in 2027, and $-72.85M in 2028.